# Veliparib and Temozolomide in Treating Patients With Acute Leukemia

> **NCT01139970** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 66 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
- Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A
- Adult Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Adult B Acute Lymphoblastic Leukemia
- Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Adult T Acute Lymphoblastic Leukemia
- Alkylating Agent-Related Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Temozolomide
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01139970
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-04
- **Primary completion:** 2014-04-15
- **Final completion:** 2018-12-01
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01139970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01139970, "Veliparib and Temozolomide in Treating Patients With Acute Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01139970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*